MELISA® is the world’s leading test for hypersensitivity to metals. It is used worldwide by dentists and doctors to determine whether a patient is intolerant to materials commonly used in dental restorations or bodily implants. New applications of the test include diagnosis of Lyme disease (Borrelia) and allergy to gluten and moulds.
MELISA® is used in:-
Dentistry Dental authorities estimate that 1 in 30 people are hypersensitive to one or more metals used in dental fillings or implants. Dentists can use MELISA® to determine whether their patients are affected – and, if so, which metals need to be removed.
Chronic fatigue syndrome and Multiple sclerosis. Hypersensitivity to heavy metals has been shown to be a significant factor in CFS and MS. In studies, 70-80% of patients who tested MELISA®-positive to metals improved after removing the offending metal.
Titanium allergy. Although titanium is considered a biocompatible metal, around 4% of all patients tested will show a positive reaction to titanium. Studies show that titanium allergic patient will improve after removal of titanium-containing implants.
Lyme disease diagnosis. MELISA® is now used in diagnosing active Lyme disease, by establishing the reactivity of the blood cells to different strains of Borrelia.
General health screening. Private health insurers include MELISA® in the panel of routine tests to establish whether a client is at risk from dental or bodily metal implants.
Orthopaedic implants. We work with orthopaedic companies who wish to minimize rejection rates by screening patients for intolerance to certain metals (i.e. chromium, titanium).
Medical research. The MELISA® test is used by researchers at the Dental Faculty in Amsterdam and First Medical Faculty, Charles University, Prague. New studies are regularly published.
Developed as a spin-off from AstraZeneca, MELISA® is available from doctors worldwide, who send blood samples to the leading laboratories where the test is conducted. Our partners include Biophage Pharma (Canada), Laboratory Center Bremen (Germany), Sabater Análisis (Spain) and Ampath (South Africa). |
